This study covered all literature published before May 15, 2017. We included case-control studies in English that compared the prevalence of vitamin D deficiency or vitamin D levels in patients with AA and in controls. Review articles, case reports, and conference reports were excluded. Odds ratios were used to compare the prevalence of vitamin D deficiency in patients with AA and controls. Continuous data were analyzed using standardized mean difference, which accounted for the varied and related to maintenance treatment interval that affected relapse. Of the patients on diphenylcyclopropenone (DPCP) maintenance treatment (MT), we first compared the treatment interval of patients who a had relapse with those who did not. Because there was a significant difference in Interval mnt itself (P ¼ .022), we focused on the change in treatment interval before and after transition to DPCP-MT. The ratio of average treatment interval before and after transition to DPCP-MT, and the time until adjustment of DPCP-MT Interval mnt were also significantly different between the relapse and nonrelapse groups (P ¼ .021, P \ .01, respectively).
Vitamin D deficiency in patients with alopecia areata: A systematic review and meta-analysis To the Editor: Alopecia areata (AA) is a T cellemediated autoimmune disease that causes nonscarring hair loss. 1 Some autoimmune diseases are associated with a vitamin D deficiency, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and vitiligo. 2, 3 Previous studies that evaluated vitamin D levels in patients with AA have reached inconsistent conclusions. This study aimed to perform a systematic review and metaanalysis on the association between vitamin D levels and AA.
This study covered all literature published before May 15, 2017. We included case-control studies in English that compared the prevalence of vitamin D deficiency or vitamin D levels in patients with AA and in controls. Review articles, case reports, and conference reports were excluded. Odds ratios were used to compare the prevalence of vitamin D deficiency in patients with AA and controls. Continuous data were analyzed using standardized mean difference, which accounted for the varied and related to maintenance treatment interval that affected relapse. Of the patients on diphenylcyclopropenone (DPCP) maintenance treatment (MT), we first compared the treatment interval of patients who a had relapse with those who did not. Because there was a significant difference in Interval mnt itself (P ¼ .022), we focused on the change in treatment interval before and after transition to DPCP-MT. The ratio of average treatment interval before and after transition to DPCP-MT, and the time until adjustment of DPCP-MT Interval mnt were also significantly different between the relapse and nonrelapse groups (P ¼ .021, P \ .01, respectively).
nonstandardized outcomes across studies. A random effects model was used for all studies because of greater heterogeneity. All analyses were performed using Comprehensive Meta-Analysis software (version 3; Biostat, Inc, Englewood, NJ).
Eleven studies including 456 patients with AA met the inclusion criteria. Studies have shown that 1,25-dihydroxyvitamin D inhibits T helper (T H ) 1 cytokine secretion and stimulates T H 2 cytokine secretion. 4 Polarization of the immune system toward the T H 2 phenotype suppresses T H 1-mediated autoimmune diseases. 4, 5 In addition, 1,25-dihydroxyvitamin D inhibits the function of T H 17 cells, which are potent inducers of autoimmune diseases. 4, 5 Additionally, it enhances regulatory T cells, which play a key role in suppressing autoimmune responses. 4, 5 Our study had several limitations. The baseline characteristics of the included subjects were heterogeneous. Serum 25-hydroxyvitamin D concentration is modulated by sex, age, ethnicity, comorbidity, diet, sun exposure level, season of blood sampling, and treatments, such as phototherapy. Subgroup analysis and metaregression were not performed because only a few studies provided detailed data on disease pattern and severity.
In conclusion, our meta-analysis found that patients with AA have a higher prevalence of 25-hydroxyvitamin D deficiency and lower 25-hydroxyvitamin D levels than the control group. Further research is needed to elucidate the underlying mechanisms and assess the efficacy of vitamin D supplementation in treating AA. Cancer risks among patients with alopecia areata: A population-based case-control study in Korea
To the Editor: Studies have shown the reduced incidence of skin cancer in patients with autoimmune dermatologic diseases, including alopecia areata (AA) and vitiligo. 1, 2 The aim of this study was to investigate the association between AA and several types of cancer. This study was a retrospective case-control study from the National Health Insurance ServiceeNational Sample Cohort. 3 Age, sex, location, income, and diagnostic codes based on the International Classification of Diseases, 10th edition were retrieved. Patients who had International Classification of Diseases, 10th edition codes of alopecia areata (L63, L63.0, L63.1, L63.2, L63.8, or L63.9) were identified from the database. Patients were identified who had International Classification of Diseases, 10th edition codes of Graves' disease (E05, E05.0 E05.8, or E05.9), Hashimoto thyroiditis (E06.3 or E06.9), thyroid (C73), breast (C50), colorectal (C18, C19, or C20), gastric (C16), liver (C22), and lung cancer (C34). To improve the accuracy of analysis, only the subjects who had $2 principal diagnostic codes for each disease were included. Control subjects matched for age and sex were selected randomly from the database at a frequency of 1:5. The demographic characteristics of study subjects were summarized in Table I (Table II) . A decreased risk of several cancers has been observed in patients with AA, although the only published study on the association between AA and cancer was with skin cancer. 1 Interestingly, in a large study of 4.5 million men, a decreased risk of cancer was observed in patients with multiple sclerosis. The innate immune profile of patients with multiple sclerosis, characterized by increased T helper type 1 immune activation and altered cytokine levels, may inhibit carcinogenesis. 4 Based on the immunologic and genomic similarities of AA with multiple sclerosis, we thought that AA might have a similar mechanism as multiple sclerosis in inhibiting carcinogenesis. We also found a significant association between AA and thyroid cancer. There were increased risks of autoimmune thyroid disease in AA patients, so it has been postulated that the inflammatory response of thyroid diseases may induce malignant transformation of the thyroid. 5 Our study has some limitations. The diagnosis of AA and various comorbidities was identified and characterized based on the claims database 
